Q-omics provides the consensus-scored TCTE3 profile across patient tissues and cancer cell-line models. TCTE3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCTE3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TCTE3 RNA expression shows 19,642 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where TCTE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCTE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCTE3 survival associations across molecular data types. TCTE3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCTE3 RNA expression–survival associations across cancer types. High TCTE3 expression shows unfavorable associations in KIRC, LIHC and ACC, but favorable associations in SCLC, PAAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCTE3 RNA expression.
This table summarizes TCTE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TCTE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCTE3 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, BLCA, STAD and LIHC. The HNSC box plot shows higher TCTE3 RNA expression in tumor versus normal tissue (log2 FC = +0.708, t-test p < 0.001).
This table shows molecular features associated with TCTE3 in patient tissues and cancer cell lines. In patient samples, TCTE3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCTE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
